BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Nathan Green

Nathan Green contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
ApplicationsComputationmath.NTMethodology

Trust snapshot

Quick read

Trust 21 - EmergingVerification L1Unclaimed author
7works
0followers
4topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

7 published item(s)

preprint2026arXiv

Population-Adjusted Indirect Treatment Comparison with the outstandR Package in R

Indirect treatment comparisons (ITCs) are essential in Health Technology Assessment (HTA) when head-to-head clinical trials are absent. A common challenge arises when attempting to compare a treatment with available individual patient data (IPD) against a competitor with only reported aggregate-level data (ALD), particularly when trial populations differ in effect modifiers. While methods such as Matching-Adjusted Indirect Comparison (MAIC) and Simulated Treatment Comparison (STC) exist to adjust for these cross-trial differences, software implementations have often been fragmented or limited in scope. This article introduces outstandR, an R package designed to provide a comprehensive and unified framework for population-adjusted indirect comparison (PAIC). Beyond standard weighting and regression approaches, outstandR implements advanced G-computation methods within both maximum likelihood and Bayesian frameworks, and Multiple Imputation Marginalization (MIM) to address non-collapsibility and missing data. By streamlining the workflow of covariate simulation, model standardization, and contrast estimation, outstandR enables robust and compatible evidence synthesis in complex decision-making scenarios.

0 citations0 reviewsNo code linkedOpen access
preprint2025arXiv

A Bayesian hierarchical mixture cure modelling framework to utilize multiple survival datasets for long-term survivorship estimates: A case study from previously untreated metastatic melanoma

Time to an event of interest over a lifetime is a central measure of the clinical benefit of an intervention used in a health technology assessment (HTA). Within the same trial, multiple end-points may also be considered. For example, overall and progression-free survival time for different drugs in oncology studies. A common challenge is when an intervention is only effective for some proportion of the population who are not clinically identifiable. Therefore, latent group membership as well as separate survival models for identified groups need to be estimated. However, follow-up in trials may be relatively short leading to substantial censoring. We present a general Bayesian hierarchical framework that can handle this complexity by exploiting the similarity of cure fractions between end-points; accounting for the correlation between them and improving the extrapolation beyond the observed data. Assuming exchangeability between cure fractions facilitates the borrowing of information between end-points. We undertake a comprehensive simulation study to evaluate the model performance under different scenarios. We also show the benefits of using our approach with a motivating example, the CheckMate 067 phase 3 trial consisting of patients with metastatic melanoma treated with first line therapy.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

BCEA: An R Package for Cost-Effectiveness Analysis

We describe in detail how to perform health economic cost-effectiveness analyses (CEA) using the R package $\textbf{BCEA}$ (Bayesian Cost-Effectiveness Analysis). CEA consist of analytic approaches for combining costs and health consequences of intervention(s). These help to understand how much an intervention may cost (per unit of health gained) compared to an alternative intervention, such as a control or status quo. For resource allocation, a decision maker may wish to know if an intervention is cost saving, and if not then how much more would it cost to implement it compared to a less effective intervention. Current guidance for cost-effectiveness analyses advocates the quantification of uncertainties which can be represented by random samples obtained from a probability sensitivity analysis or, more efficiently, a Bayesian model. $\textbf{BCEA}$ can be used to post-process the sampled costs and health impacts to perform advanced analyses producing standardised and highly customisable outputs. We present the features of the package, including its many functions and their practical application. $\textbf{BCEA}$ is valuable for statisticians and practitioners working in the field of health economic modelling wanting to simplify and standardise their workflow, for example in the preparation of dossiers in support of marketing authorisation, or academic and scientific publications.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trial in Health Technology Assessment

Background Survival extrapolation is essential in the cost-effectiveness analysis to quantify the lifetime survival benefit associated with a new intervention, due to the restricted duration of randomized controlled trials (RCTs). Current approaches of extrapolation often assume that the treatment effect observed in the trial can continue indefinitely, which is unrealistic and may have a huge impact on decisions for resource allocation. Objective We introduce a novel methodology as a possible solution to alleviate the problem of performing survival extrapolation with heavily censored data from clinical trials. Method The main idea is to mix a flexible model (e.g., Cox semi-parametric) to fit as well as possible the observed data and a parametric model encoding assumptions on the expected behaviour of underlying long-term survival. The two are "blended" into a single survival curve that is identical with the Cox model over the range of observed times and gradually approaching the parametric model over the extrapolation period based on a weight function. The weight function regulates the way two survival curves are blended, determining how the internal and external sources contribute to the estimated survival over time. Results A 4-year follow-up RCT of rituximab in combination with fludarabine and cyclophosphamide v. fludarabine and cyclophosphamide alone for the first-line treatment of chronic lymphocytic leukemia is used to illustrate the method. Conclusion Long-term extrapolation from immature trial data may lead to significantly different estimates with various modelling assumptions. The blending approach provides sufficient flexibility, allowing a wide range of plausible scenarios to be considered as well as the inclusion of genuine external information, based e.g. on hard data or expert opinion. Both internal and external validity can be carefully examined.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Algebraic Relations among Goss's Zeta Values on Elliptic Curves

In 2007 Chang and Yu determined all the algebraic relations among Goss's zeta values for the rational function field - these are also known as the Carlitz zeta values. Goss raised the problem about algebraic relations among Goss's zeta values for a general base ring A, but very little is known. In this paper we develop a general method and determine all algebraic relations among Goss's zeta values for the base ring A attached to an elliptic curve over a finite field. To our knowledge, these are the first non-trivial solutions of Goss's problem for a base ring whose class number is strictly greater than 1.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

On Log-Algebraic Identities for Anderson t-modules and Characteristic p Multiple Zeta Values

Based on the notion of Stark units we present a new approach that obtains refinements of log-algebraic identities for Anderson t-modules. As a consequence, we establish a generalization of Chang's theorem on logarithmic interpretations for special characteristic p multiple zeta values (MZV's) and recover many earlier results in this direction. Further, we devise a direct and conceptual way to get logarithmic interpretations for both MZV's and v-adic MZV's. This generalizes completely the work of Anderson and Thakur for Carlitz zeta values.

0 citations0 reviewsNo code linkedOpen access
preprint2010arXiv

A Novel Chronic Disease Policy Model

We develop a simulation tool to support policy-decisions about healthcare for chronic diseases in defined populations. Incident disease-cases are generated in-silico from an age-sex characterised general population using standard epidemiological approaches. A novel disease-treatment model then simulates continuous life courses for each patient using discrete event simulation. Ideally, the discrete event simulation model would be inferred from complete longitudinal healthcare data via a likelihood or Bayesian approach. Such data is seldom available for relevant populations, therefore an innovative approach to evidence synthesis is required. We propose a novel entropy-based approach to fit survival densities. This method provides a fully flexible way to incorporate the available information, which can be derived from arbitrary sources. Discrete event simulation then takes place on the fitted model using a competing hazards framework. The output is then used to help evaluate the potential impacts of policy options for a given population.

0 citations0 reviewsNo code linkedOpen access